{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:02:33Z","timestamp":1789916553599,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Phospholamban is an endogenous sarcoplasmic reticulum calcium ATPase inhibitor with a regulatory effect on cardiac contraction\/relaxation coupling. Mutations in the phospholamban gene (PLN) have been associated with primary cardiomyopathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To screen for PLN mutations in our population of patients with primary cardiomyopathies and to perform functional analysis of the mutations identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed SSCP mutational screening and DNA sequencing of the PLN gene in 186 patients with either hypertrophic or dilated cardiomyopathy. To study promoter strength we constructed reporter plasmids containing the luciferase gene and performed transient transfection analysis in C6 and C2C12 cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PLN \u201342 C&amp;gt;G mutation was found in one patient with late onset familial apical hypertrophic cardiomyopathy. This mutation decreased phospholamban promoter activity by 43% and 47%, in C6 and C2C12 cell lines respectively. One son had mild apical hypertrophic cardiomyopathy and carried the mutation, another son with normal ECG and echocardiogram also had the mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PLN \u201342 C&amp;gt;G mutation is associated with a benign form of apical hypertrophic cardiomyopathy in this family, though the presence of a healthy adult carrier suggests that other genetic and environmental factors could be involved. Otherwise, mutations in the PLN gene are not a frequent cause of cardiomyopathies in our population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ejheart.2006.04.007","type":"journal-article","created":{"date-parts":[[2006,7,8]],"date-time":"2006-07-08T07:20:12Z","timestamp":1152343212000},"page":"37-43","source":"Crossref","is-referenced-by-count":47,"title":["Mutational Screening of Phospholamban Gene in Hypertrophic and Idiopathic Dilated Cardiomyopathy and Functional Study of the PLN \u201342 C&amp;gt;G Mutation"],"prefix":"10.1093","volume":"9","author":[{"given":"Maria","family":"Medin","sequence":"first","affiliation":[{"name":"Hospital Universitario Juan Canalejo \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Hermida-Prieto","sequence":"additional","affiliation":[{"name":"Hospital Universitario Juan Canalejo \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Monserrat","sequence":"additional","affiliation":[{"name":"Hospital Universitario Juan Canalejo \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Laredo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Juan Canalejo \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Carlos","family":"Rodriguez-Rey","sequence":"additional","affiliation":[{"name":"Hospital Universitario Juan Canalejo \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xustox","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Juan Canalejo \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Castro-Beiras","sequence":"additional","affiliation":[{"name":"Hospital Universitario Juan Canalejo \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,1,14]]},"reference":[{"key":"2026020203453597600_ejhf2006-04-007-bib-0001","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","article-title":"ACC\/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy)","volume":"42","author":"Maron","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0300-8932(00)75069-X","article-title":"Identification and treatment of patients with hypertrophic cardiomyopathy at risk of sudden death","volume":"53","author":"McKenna","year":"2000","journal-title":"Rev Esp Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0003","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","article-title":"Hypertrophic cardiomyopathy: a systematic review. Review","volume":"287","author":"Maron","year":"2002","journal-title":"JAMA"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1034\/j.1399-0004.2003.00151.x","article-title":"Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy","volume":"64","author":"Erdmann","year":"2003","journal-title":"Clin Genet"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0005","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"EUROGENE Heart Failure Project. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy","volume":"107","author":"Richard","year":"2003","journal-title":"Circulation"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0006","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/01.CIR.0000080896.52003.DF","article-title":"Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy","volume":"108","author":"Van Driest","year":"2003","journal-title":"Circulation"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0007","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2004.04.039","article-title":"Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy","volume":"44","author":"Van Driest","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0008"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI200317612","article-title":"Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies","volume":"111","author":"Chien","year":"2003","journal-title":"J Clin Invest"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0010","first-page":"7","article-title":"Familial dilated cardiomyopathy. Current status and clinical benefits of basic research","volume":"56","author":"Castro-Beiras","year":"2003","journal-title":"Rev Esp Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0011","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/01.RES.72.2.463","article-title":"Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium","volume":"72","author":"Arai","year":"1993","journal-title":"Circ Res"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0012","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/01.CIR.92.4.778","article-title":"Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy","volume":"92","author":"Meyer","year":"1995","journal-title":"Circulation"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0008-6363(97)00277-0","article-title":"Alterations of calcium-regulatory proteins in heart failure. Review","volume":"37","author":"Hasenfuss","year":"1998","journal-title":"Cardiovasc Res"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0014","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1081578","article-title":"Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban","volume":"299","author":"Schmitt","year":"2003","journal-title":"Science"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1172\/JCI17892","article-title":"Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human","volume":"111","author":"Haghighi","year":"2003","journal-title":"J Clin Invest"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-291X(03)00526-6","article-title":"Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy","volume":"304","author":"Minamisawa","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0017","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0018","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1432-1327.1998.2580744.x","article-title":"Involvement of NF-Y in transcriptional regulation of the phospholamban gene","volume":"258","author":"Yabuki","year":"1998","journal-title":"Eur J Biochem"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00926876","article-title":"Expression of phospholamban in C2C12 cells and regulation of endogenous SERCA1 activity","volume":"146","author":"Harrer","year":"1995","journal-title":"Mol Cell Biochem"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0092-8674(00)81662-1","article-title":"Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy","volume":"99","author":"Minamisawa","year":"1999","journal-title":"Cell"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0021","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1172\/JCI18716","article-title":"Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats","volume":"113","author":"Iwanaga","year":"2004","journal-title":"J Clin Invest"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0022","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI200316738","article-title":"Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy","volume":"111","author":"Song","year":"2003","journal-title":"J Clin Invest"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0023","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0006-291X(92)91144-F","article-title":"Identification of a highly conserved region at the 5\u2032 flank of the phospholamban gene","volume":"188","author":"Johns","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0024","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1006\/jmcc.1998.0904","article-title":"The human phospholamban gene: structure and expression","volume":"31","author":"McTiernan","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJM199804303381802","article-title":"Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy","volume":"338","author":"Niimura","year":"1998","journal-title":"N Engl J Med"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0026","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jacc.2004.08.052","article-title":"Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. Review","volume":"44","author":"Maron","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0027","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/0735-1097(95)00390-8","article-title":"Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients","volume":"26","author":"Klues","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0028","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/0002-9149(82)90200-4","article-title":"Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy)","volume":"49","author":"Maron","year":"1982","journal-title":"Am J Cardiol"},{"key":"2026020203453597600_ejhf2006-04-007-bib-0029","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0002-9149(88)91233-7","article-title":"Familial apical hypertrophic cardiomyopathy","volume":"62","author":"Penas","year":"1988","journal-title":"Am J Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2006.04.007","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/1\/37\/66615356\/eurjhf_9_1_37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/9\/1\/37\/66615356\/eurjhf_9_1_37.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:45:47Z","timestamp":1770021947000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/9\/1\/37\/8443632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,1,14]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2006.04.007","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,1]]},"published":{"date-parts":[[2007,1,1]]}}}